ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0293 • ACR Convergence 2020

    Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus

    Robert Clancy1, Miranda Marion2, Peter Izmirly3, Mala Masson4, Hannah Ainsworth2, Timothy Howard5, Jill Buyon6 and Carl Langefeld7, 1NYU School of Medicine, New York, 2Wake Forest School of Medicine, Winston-Salem, 3Department of Medicine, New York University School of Medicine, New York, NY, 4New York University School of Medicine, New York, 5Wake Forest School of Medicine, Winston-Salem, NC, 6Department of Medicine, NYU School of Medicine, New York, NY, 7Wake Forest School of Medicine, Winston Salem, NC

    Background/Purpose: Anti-Ro autoantibody production often precedes the development of systemic lupus erythematosus (SLE) or Sjögren’s syndrome (SS) by years. Anti-Ro+ mothers of children with manifestations…
  • Abstract Number: 0437 • ACR Convergence 2020

    Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting

    Jun Chu1, Sarthak Gupta1, Zerai Manna2, Michael Davis1, Yenealem Temesgen-Oyelakin1, Elaine Poncio1, Isabel Ochoa1, Laura Lewandowski3, Mariana Kaplan4, Alan Decherney1 and Sarfaraz Hasni2, 1National Institutes of Health, Bethesda, MD, 2Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, 3NIAMS, NIH, Rockville, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) predominantly affects women of childbearing age. Women affected by SLE have higher risk for infertility, miscarriages, and other pregnancy complications…
  • Abstract Number: 0575 • ACR Convergence 2020

    The Impact of an Integrated Care Management Program on Acute Care Utilization and Outpatient Appointment Attendance Among High-Risk Patients with Lupus

    Jessica Williams1, Weixing Huang2, Jamie Collins3, Kreager Taber1, Katherine McLaughlin1, Rebecca Cunningham1, Christine Vogeli4, Lisa Wichmann1 and Candace Feldman3, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, 3Brigham and Women's Hospital, Boston, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are often members of disadvantaged groups and some struggle with high acute care utilization and missed outpatient appointments.…
  • Abstract Number: 0841 • ACR Convergence 2020

    CD6 Modulation Ameliorates Kidney and Skin Disease in a Spontaneous Murine Lupus Model

    Samantha Chalmers1, Sayra Garcia1, Rajalakshmy Ayilam Ramachandran2, Chandra Mohan2, Leal Herlitz3, Dalena Chu4, Jeanette Ampudia4, Cherie Ng5, Stephen Connelly4 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Houston, Houston, TX, 3Cleveland Clinic, Cleveland, OH, 4Equillium, Inc, San Diego, CA, 5Equillium, Inc, La Jolla, CA

    Background/Purpose: T cells are an important contributor to the pathogenesis of SLE and lupus nephritis, and thus present themselves as interesting therapeutic targets. CD6 is…
  • Abstract Number: 0860 • ACR Convergence 2020

    PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE

    Paul Dunford1, Gail Comer1, Ralph Raymond1, Donald Jung1, Paul Moore2, Francisco Leon1 and Joan Merrill3, 1Provention Bio, Oldwick, NJ, 2MacroGenics, Rockville, MD, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders.  A desired improvement in efficacy and safety necessitate the development of alternate,…
  • Abstract Number: 0948 • ACR Convergence 2020

    Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus

    Ricardo Grieshaber-Bouyer1, Joshua Keegan2, Peter Nigrovic3, James Lederer4 and Deepak Rao2, 1Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, 2Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, 4BWH Harvard Medical School, Boston, MA

    Background/Purpose: Neutrophils are important effector cells in systemic immune-mediated diseases. Neutrophil phenotypes vary depending on their age, maturity, activation state, and local environment; however, differences…
  • Abstract Number: 1019 • ACR Convergence 2020

    Outdoor Air Pollution and Systemic Lupus Erythematosus

    George Stojan1, Anton Kvit2, Frank Curriero2 and Michelle Petri3, 1Johns Hopkins University, BALTIMORE, MD, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, 3Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: Understanding the role of environmental exposures in the development of SLE and their association with SLE activity may help identify modifiable risk factors and…
  • Abstract Number: 1257 • ACR Convergence 2020

    Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus

    Sofia Gernaat1, Julia Simard2, Elisabet Svenungsson3 and Elizabeth Arkema4, 1Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 2Stanford Medicine, Stanford, CA, 3Karolinska University Hospital, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Increased insulin resistance is pivotal in the development of gestational diabetes mellitus (GDM). Women with SLE may be at higher risk of GDM due…
  • Abstract Number: 1274 • ACR Convergence 2020

    COVID-19 in Patients with Systemic Lupus Erythematosus

    Ruth Fernandez-Ruiz1, Mala Masson1, Mimi Kim2, Benjamin Myers3, Rebecca Haberman4, Jose Scher4, Rochelle Castillo4, Allison Guttmann1, Philip Carlucci1, Kristina Deonaraine1, Michael Golpanian5, Kimberly Robins1, Miao Chang1, H. Michael Belmont6, Jill Buyon7, Ashira Blazer6, Amit Saxena8 and Peter Izmirly9, 1New York University School of Medicine, New York, 2Albert Einstein College of Medicine, Bronx, 3Cornell University, Ithica, NY, 4NYU School of Medicine, New York City, 5New York University, New York, NY, 6NYU School of Medicine, New York, NY, 7Department of Medicine, NYU School of Medicine, New York, NY, 8NYU School of Medicine, New York, 9Department of Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…
  • Abstract Number: 1290 • ACR Convergence 2020

    A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous

    Mitra Moazzami1, Patricia Katz2, Dennisse Bonilla3, Lisa Engel4, Jiandong Su5, Pooneh Akhavan6, Nicole Anderson5, Oshrat Tayer-Shifman7, Dorcas Beaton8 and Zahi Touma9, 1George Washington University School of Medicine, Washington, DC, 2University of California, San Francisco, Novato, CA, 3University Health Network, Toronto, Canada, 4University of Manitoba, Toronto, ON, Canada, 5University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 6Univesity of Toronto, Toronto, ON, Canada, 7Meir Medical Center, Raanana, Israel, 8Institue for Work and Health, Toronto, ON, Canada, 9University of Toronto, Toronto, ON, Canada

    Background/Purpose: Use of The Patient Reported Outcomes Measurement Information System computerized adaptive test (PROMIS-CAT) in adults with systemic lupus erythematous (SLE) is an emerging research…
  • Abstract Number: 1454 • ACR Convergence 2020

    B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice

    Haylee Baxendell1, Minjung Kim2, Jeremy Tilstra2 and Mark Shlomchik2, 1University of Pittsburgh, Cranberry Twp, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that results in significant morbidity and mortality. In SLE, endosomal TLR7 and TLR9 are known to…
  • Abstract Number: 1553 • ACR Convergence 2020

    Optical Tomography Can Accurately Diagnose Lupus Arthritis

    Wei Tang1, Alessandro Marone2, Youngwan Kim2, Tommy Chen1, Cathy Guo1, Leila Khalili1, Andreas Hielscher2 and Anca Askanase3, 1Columbia University Medical Center, New York, NY, 2Columbia University, New York, NY, 3Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: Incapacitating inflammatory arthritis occurs in up to 88% of patients with systemic lupus erythematosus (SLE). Arthritis is present in 70-80% of lupus patients in…
  • Abstract Number: 1675 • ACR Convergence 2020

    Microstructural Damage Is Associated with Age at Disease-onset and Cognitive Impairment in Systemic Lupus Erythematosus

    Paulo Julio1, Renan Frittoli1, Aline Lapa1, Thais Caldeira1, Leticia Rittner1, Fernando Cendes1, Roberto Marini1, Paula Fernandes1, Lilian Costallat1 and Simone Appenzeller1, 1UNICAMP, Campinas, Brazil

    Background/Purpose: To compare corpus callosum (CC) volume and diffusion tensor imaging in systemic lupus erythematosus according to age of disease-onset. Methods: We selected 75 patients with…
  • Abstract Number: 1785 • ACR Convergence 2020

    Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases

    Jazzia Emily Diaz-Angulo1, Cassandra M. Skinner-Taylor1, Lorena Perez-Barbosa1, Eugenio Salvador Barriga-Maldonado1, Marco Valdovinos2, Rita Pineda-Sic1, Jesus Alberto Cardenas-de la Garza1, Gabriel Figueroa-Parra3, Janett Carmen Riega-Torres4 and Dionicio Ángel Galarza-Delgado5, 1Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey, Nuevo Leon, Mexico, 2Hospital Universitario José Eleuterio González, Monterrey, Nuevo Leon, Mexico, 3Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey NL, Nuevo Leon, Mexico, 5Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: The importance of safe and effective contraception for women with rheumatic diseases has been increasing. Several studies have demonstrated that carefully planned pregnancies are…
  • Abstract Number: 1805 • ACR Convergence 2020

    Longitudinal Analysis of IFN Status and Disease Characteristics in SLE

    Melissa Northcott1, Alberta Hoi2, Rachel Koelmeyer3 and Eric Morand4, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Monash University, Clayton, Victoria, Australia, 4Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: The type 1 interferon (IFN) cytokine family is key to the pathogenesis of SLE, evidenced by the expression of IFN stimulated genes (ISGs) in…
  • « Previous Page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology